Cyclopharm Limited (ASX:CYC) Responds to ASX Price Inquiry
Trading Activity Overview
Cyclopharm Limited (ASX:CYC) addressed recent trading activity following an inquiry from the ASX. The company noted a price fluctuation, with shares moving from a low of $1.65 to a high of $2.23 on January 6, 2025, alongside a significant increase in trading volume.
ASX Query Response
In response to the ASX’s questions, Cyclopharm confirmed it is not aware of any undisclosed information that might explain the trading activity. Managing Director Mr. James McBrayer stated, “The Company is carrying on business in the ordinary course in accordance with its disclosed strategic direction and commercialisation plan.”
Compliance Assurance
The company affirmed its compliance with ASX Listing Rules, specifically Rule 3.1, which concerns the disclosure of information that could affect securities prices. The responses provided to the ASX were authorised and approved as per Cyclopharm’s continuous disclosure policy.
Conclusion
Cyclopharm Limited assures its stakeholders of operational normalcy and adherence to regulatory requirements amid trading activity.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.